Opus Genetics CEO sells shares for tax withholding

Opus Genetics, Inc. Chief Executive Officer George Magrath reported an automatic sale of 9,475 shares of common stock on July 23, 2026 to satisfy tax withholding obligations arising from a restricted stock unit vesting.

Rhea-AI Filing Summary

Opus Genetics, Inc. Chief Executive Officer George Magrath reported an automatic sale of 9,475 shares of common stock on July 23, 2026 to satisfy tax withholding obligations arising from a restricted stock unit vesting. The shares were sold at a weighted average price of $2.9473, within a $2.9009–$3.025 range, leaving 1,731,869 directly held shares after the transaction. The sale did not represent a discretionary trade by the reporting person, and the Rule 10b5‑1 trading plan checkbox for the filing was not selected.

Insider Trade Summary

Net Seller: 9,475 shares

Net Sell 1 txn

Insider Magrath George

Role Chief Executive Officer

Sold 9,475 shs ($28K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	9,475	$2.9473	$28K

Holdings After Transaction: Common Stock — 1,731,869 shares (Direct)

Footnotes (2)

1. F1. The shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Company to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award. This transaction does not represent a discretionary trade by the Reporting Person.
2. F2. The price in column 4 represents the weighted average price. The shares were sold in multiple transactions at prices ranging from $2.9009 to $3.025, inclusive. The Reporting Person undertakes to provide the issuer, any securityholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 9,475 shares Weighted average sale price: $2.9473 per share Sale price range: $2.9009–$3.025 per share +1 more

4 metrics

Shares sold 9,475 shares Common stock sale on July 23, 2026

Weighted average sale price $2.9473 per share Common stock sale on July 23, 2026

Sale price range $2.9009–$3.025 per share Multiple transactions within stated range

Shares held after transaction 1,731,869 shares Directly owned common stock after the sale

Key Terms

restricted stock units, weighted average price, tax withholding obligations, non-derivative

4 terms

restricted stock units financial

"vesting and settlement event from a restricted stock units award"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average price financial

"The price in column 4 represents the weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

tax withholding obligations financial

"required by the Company to satisfy tax withholding obligations"

non-derivative financial

"transaction_type": "non-derivative"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Opus Genetics (IRD) CEO George Magrath report?

George Magrath reported an automatic sale of 9,475 shares of Opus Genetics common stock. The sale occurred on July 23, 2026 and was executed to cover tax withholding obligations related to a restricted stock unit vesting event.

At what price were the Opus Genetics (IRD) shares sold by CEO George Magrath?

The shares were sold at a weighted average price of $2.9473 per share. According to the disclosure, multiple trades occurred in a price range from $2.9009 to $3.025, and full trade-by-trade details are available on request.

Why were George Magrath’s Opus Genetics (IRD) shares sold?

The shares were sold automatically to satisfy tax withholding obligations tied to the vesting and settlement of a restricted stock unit award. The company required this sale, and it is explicitly described as not being a discretionary trade by Magrath.

How many Opus Genetics (IRD) shares does CEO George Magrath hold after this sale?

After the reported sale, George Magrath directly holds 1,731,869 shares of Opus Genetics common stock. This figure reflects his remaining direct ownership position immediately following the 9,475-share sale executed for tax withholding purposes.

Was George Magrath’s Opus Genetics (IRD) sale under a Rule 10b5-1 trading plan?

The sale is described as automatic and non-discretionary for tax withholding, but the Rule 10b5-1 trading plan checkbox on the filing was not selected. The disclosure does not identify the transaction as occurring under a Rule 10b5-1 plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/27/2026 - 04:07 PM Accepted by SEC EDGAR 07/27/2026 - 04:07 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Magrath George

(Last) (First) (Middle)

C/O OPUS GENETICS, INC.

8 DAVIS DRIVE, SUITE 220

(Street)

DURHAM NORTH CAROLINA 27713

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Opus Genetics, Inc. [ IRD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/23/2026		S(1)		9,475	D	$2.9473(2)	1,731,869	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Company to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award. This transaction does not represent a discretionary trade by the Reporting Person.

2. The price in column 4 represents the weighted average price. The shares were sold in multiple transactions at prices ranging from $2.9009 to $3.025, inclusive. The Reporting Person undertakes to provide the issuer, any securityholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ Amy Rabourn, by Power of Attorney	07/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)